Although IL-1α-NP has the potential to be a viable immunotherapy for EGFR-bearing HNSCC patients, whether it can still be therapeutically useful in HNSCC patients with EGFR mutations requires further investigation. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.